So did a bit of a 5 year hypothetical blueprint to see what numbers look like under some variable key assumptions.
Upper Range Scenario (8% JAWS)
Key Assumptions Used:
- Revenue 13% CAGR
- Expenses 5% CAGR
- PE (normalised NPAT) 40x Plus Cash
Further Information Used:
- Cash Benefits (from tax and amortization assets) $19m
- Share Based Payments $2m p.a
Next 5 Years ($):
Revenue 30m, 34m, 39m, 44m, 49m
Expenses 27m 28m 29m 31m 32m
Normalised NPAT 2m, 4m, 7m, 10m, 13m
Cash Inflow 5m, 8m, 12m, 15m, 19m
2027 Result ($):
Normalised NPAT 13m
Cash Balance 84m
Market Cap 604m
Shareholder Return 4.4x or 35% CAGR
Middle Range Scenario (4% JAWS)
Key Assumptions Used:
- Revenue 9% CAGR
- Expenses 5% CAGR
- PE (normalised NPAT) 35x Plus Cash
Further Information Used:
- Cash Benefits (from tax and amortization assets) $19m
- Share Based Payments $2m p.a
Next 5 Years ($):
Revenue 29m, 32m, 35m, 38m, 41m
Expenses 27m 28m 30m 32m 34m
Normalised NPAT 1m, 3m, 3m, 4m, 5m
Cash Inflow 4m, 6m, 7m, 8m, 9m
2027 Result ($):
Normalised NPAT 5m
Cash Balance 59m
Market Cap 229m
Shareholder Return 1.67x or 11% CAGR
Lower Range Scenario (2% JAWS)
Key Assumptions Used:
- Revenue 9% CAGR
- Expenses 7% CAGR
- PE (normalised NPAT) 30x plus Cash
Further Information Used:
- Cash Benefits (from tax and amortization assets) $19m
- Share Based Payments $2m p.a
Next 5 Years ($):
Revenue 29m, 32m, 35m, 38m, 42m
Expenses 29m 31m 33m 35m 38m
Normalised NPAT 0m, 1m, 2m, 2m, 3m
Cash Inflow 2m, 3m, 4m, 5m, 6m
2027 Result ($):
Normalised NPAT 3m
Cash Balance 45m
Market Cap 135m
Shareholder Return 0% or 0% CAGR
-----
Takeaway
Revenue beats Expenses by 2% p.a = avoids losses with a return of investment @ 0% cagr
Revenue beats Expenses by 5% p.a = performs a market average returns @ 11% cagr
Revenue beats Expenses by 8% p.a = achieves multifold excess return @ 35% cagr
(hopefully no minor errors as going through this was for my own mind more than for external presentation)
- Forums
- ASX - By Stock
- M7T
- Ann: Annual Report to shareholders FY2022
M7T
mach7 technologies limited
Add to My Watchlist
2.63%
!
37.0¢

Ann: Annual Report to shareholders FY2022, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $86.93M |
Open | High | Low | Value | Volume |
38.0¢ | 38.0¢ | 37.0¢ | $13.56K | 36.50K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1078 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 59643 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1078 | 0.370 |
2 | 5557 | 0.360 |
1 | 50000 | 0.355 |
3 | 54855 | 0.350 |
1 | 18411 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 59643 | 2 |
0.385 | 35000 | 1 |
0.390 | 39520 | 1 |
0.400 | 71231 | 1 |
0.410 | 105000 | 2 |
Last trade - 15.36pm 01/08/2025 (20 minute delay) ? |
Featured News
M7T (ASX) Chart |
The Watchlist
AFP
AFT PHARMACEUTICALS LIMITED
Hartley Atkinson, CEO & Founder
Hartley Atkinson
CEO & Founder
Previous Video
Next Video
SPONSORED BY The Market Online